CANBERA (dpa-AFX) - Telix Pharmaceuticals Limited (TLX, TLX.AX) on Tuesday reported a rise in revenue for the fourth quarter, helped by increased revenue from the Precision Medicine segment and RLS third-party.
For the three-month period to December 31, 2025, the company posted revenue of $208 million, higher than $142 million in the same period last year.
Revenue from the Precision Medicine segment moved up to $161 million from $139 million a year ago. RLS third-party revenue stood at $45 million, compared with $00.00 million last year.
TLX was down by 1.03% at $7.68 in the pre-market trade on the Nasdaq.
Copyright(c) 2026 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2026 AFX News
